Gastritis Treatment Market Size by Drug Class, Type, End User, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2034
Overview
The Gastritis Treatment Market size was valued at USD 5.5 Bn in 2025, and the total Gastritis Treatment Market revenue is growing at a CAGR of 4.5% from 2026 to 2034, reaching USD 8.17 Bn by 2034.
Gastritis Treatment Market Overview
The gastritis treatment market encompasses a broad range of therapeutic solutions aimed at alleviating inflammation of the stomach lining caused by factors such as Helicobacter pylori (H. pylori) infection, prolonged use of NSAIDs, stress, and autoimmune conditions. This market includes prescription medications like proton pump inhibitors (PPIs), antacids, antibiotics, H2-receptor antagonists, and protective agents, offering an in-depth perspective on the available treatment classes. The report evaluates these therapeutic categories, providing clarity on their role in managing gastritis across diverse patient populations.
The gastritis treatment market is influenced by several key growth drivers, including a rising prevalence of gastrointestinal disorders, an expanding geriatric population, and changing dietary habits shaped by the aggressive marketing strategies of the global food industry. Additionally, the report examines the market’s supply chain, highlighting the availability of active compounds and the role of the generic drug segment, particularly generic drug manufacturing in cost-effective regions, which supports affordability and accessibility for patients worldwide.
From a regional perspective, the gastritis treatment market is dominated by North America in 2025, owing to its advanced healthcare infrastructure, higher diagnosis rates, and well-established surgical and diagnostic capabilities. Europe follows closely due to strong healthcare systems and increasing awareness. Meanwhile, the Asia-Pacific market is forecast to witness substantial growth, driven by a combination of rising healthcare access and increased global demand for gastritis treatments. The report also profiles major players shaping the competitive landscape, including Pfizer Inc., GlaxoSmithKline plc, AstraZeneca, and Takeda Pharmaceutical Company Limited.
Furthermore, the gastritis treatment market report outlined key opportunities and potential growth avenues beyond traditional hospital settings. This includes the role of retail pharmacies, chain drugstores, and online platforms as important end-user segments. By detailing market drivers and emerging trends, the report provides strategic insights into how industry stakeholders can capture market share within the broader gastric mucosal disease treatment ecosystem.
Gastritis Treatment Market Growth and Share Analysis
To know about the Research Methodology :- Request Free Sample Report
Gastritis Treatment Market Dynamics
Rising Prevalence of Gastrointestinal Disorders to Drive Gastritis Treatment Market Growth
The gastritis treatment market is primarily driven by the increasing global prevalence of gastrointestinal disorders, including gastritis, which affects millions annually due to factors such as poor dietary habits, stress, excessive alcohol consumption, and widespread use of NSAIDs. Additionally, the growing aging population is more susceptible to digestive issues, which further boosts the demand for effective treatment options. The report highlights that this rising disease burden has led to increased healthcare spending and greater adoption of advanced diagnostic and therapeutic solutions, significantly propelling market growth.
Side Effects and Misdiagnosis Risks to Create Gastritis Treatment Market Restraints
A key restraint in the gastritis treatment market is the potential side effects associated with long-term use of medications such as proton pump inhibitors (PPIs) and antibiotics, which can lead to issues like nutrient malabsorption or antibiotic resistance. Moreover, the similarity of gastritis symptoms with other gastrointestinal conditions often results in misdiagnosis or delayed treatment, hampering timely intervention. As highlighted in the report, these factors can limit patient adherence and pose challenges for healthcare providers, thereby restricting market expansion.
Advancements in Personalized Medicine and Diagnostics to Create Gastritis Treatment Market Opportunity
The gastritis treatment market presents significant growth opportunities through advancements in personalized medicine and diagnostic technologies. Innovations such as non-invasive testing, genetic profiling, and biomarker-based diagnostics enable more accurate detection and tailored treatment plans, improving patient outcomes. The report emphasizes that increased research investments and the integration of AI in gastroenterology offer potential for early diagnosis and targeted therapies, especially for chronic and H. pylori-induced gastritis, unlocking new avenues for market players.
Global Gastritis Treatment Market Segment Analysis
Based on type, the acute gastritis segment dominated the Gastritis Treatment Market, with a market size of USD xx Bn in 2025 and is estimated to grow at a CAGR of xx% during 2026-2034. Acute Gastritis is caused by the overuse of NSAIDs (Non-Steroidal Anti-Inflammatory) drugs like sodium naproxen, ibuprofen, and diclofenac, with complications such as hemorrhages and erosion. It is analyzed by antacids like famotidine (Pepcid) and proton pump inhibitors that aid in the suppression of excessive acid production, assisting in the global market’s growth. The MMR report will provide an accurate prediction of the contribution of the various segments, like type, drug class, and end user, to the growth of the gastritis treatment market size.
Global Gastritis Treatment Market Regional Insights
North America accounted for the largest market share in 2025, with a market value of US$ xx Mn; the regional market is expected to register a CAGR of xx% during 2026-2034. Fast food chains' broad presence in this region, as well as a developing sedentary lifestyle culture, which contributes to a growing gastritis patient pool and a growing geriatric population, are expected to boost the growth of the gastritis treatment market. Furthermore, increased alcohol abuse, as well as the presence of major key players, are expected to propel the market forward. According to a published poll, nearly one in every 100 people in the US suffers from gastritis. As a result, the market will develop faster during the anticipated period as the patient population grows. Furthermore, factors such as increased government initiatives and funding for research, advancements in advanced medical treatment choices, and the availability of beneficial reimbursement policies are expected to drive the expansion of the gastritis treatment market in the US.
Europe occupied the second largest market share of xx% in 2025, thanks to the availability of advanced treatment facilities, recognised healthcare infrastructure, along the presence of a flourishing medical device market, which helps in efficient and accurate diagnosis. Furthermore, due to the increasing number of lactose-intolerant issues, vulnerability to falling prey to gastritis is more likely to lead to an increasing number of gastritis sufferers. Thus, fuelling the market growth during the forecast period.
The objective of the report is to present a comprehensive analysis of the global Gastritis Treatment Market to the stakeholders in the industry. The past and current status of the industry, with the forecasted market size and trends, are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear, futuristic view of the industry to the decision-makers.
The report also helps in understanding the global Gastritis Treatment Market dynamics, structure by analyzing the market segments and projects the global Gastritis Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global Gastritis Treatment Market makes the report an investor’s guide.
Gastritis Treatment Market Competitive Landscape
The competitive landscape of the Gastritis Treatment Market is dominated by two organizations, Pfizer Inc. and AstraZeneca plc. The stronghold of Pfizer in the market share of gastritis treatments is due to pharmacy availability of both prescription medications and OTC products in numerous formulations, including proton pump inhibitors, PPIs and antibiotics. With a strong, established distribution network in hospitals, pharmacies and e-commerce and ongoing research and development to improve drug effectiveness and bioavailability, they continue to expand their market share. Pfizer also continues to develop new formulations, through mergers and acquisitions, distribution or marketing intermediaries, and to seek ways of understanding product effectiveness.
AstraZeneca has a well-known product, Nexium, that is one of the most common and potent prescription medications for gastritis, which is usually symptomatic of acid-related gastric disorders. Because they continue to innovate in next-generation phosphodiesterase delivery systems and also invest multi-million dollars in R&D in acid-suppressing therapies, they maintain a priority in the development of acid suppressors in the pharmacy chain. AstraZeneca also has an extensive pipeline of products in development on a routine basis, and frequently works with partners and in other corporate relationships to increase its reach in the market. These two companies together have strong advantages in the gastritis treatment market and they have a strong negotiating effect in driving treatment advancement and patient experience in the North American Gastritis market as they leverage their science, products, and strategic goals in the market.
Gastritis Treatment Market Key Trends
1. Move Toward the Development of More Targeted and Personalized Therapies
The FDA fast-tracking approval of biologic therapies, and the research and approval of new precision medicine signal a clear trend to deal with the root causes of gastritis, such as H.pylori-induced mucosal inflammation damage. Companies are heroically pivoting to patient-specific therapy development, rather than just being mired in symptom management, further suggesting a movement toward personalized care strategies in the field of gastroenterology.
2. Adoption of Artificial Intelligence and Advanced Research and Development Technologies
The emergence of AI-based drug discovery platforms espouses the pharmaceutical industry’s adoption of artificial intelligence and machine learning to find new compounds, while expediting process timeframes. This exemplifies a larger transformative phase of drug research through digital adaptation and R&D methodology transformation, which increasingly shapes research, reduces costs, and enriches research-through-data.
Gastritis Treatment Market Recent Industry Development
| Date | Company | Development | Impact |
|---|---|---|---|
| 15 January 2025 | Takeda Pharmaceutical Company Limited | Takeda expanded its commercial distribution network for vonoprazan (TAK-438) to enhance global patient access for acid-related gastric disorders, including severe gastritis. | The expansion accelerates market adoption of potassium-competitive acid blockers (P-CABs) over traditional proton pump inhibitors. |
| 11 March 2025 | AstraZeneca | AstraZeneca initiated advanced Phase III clinical evaluations for a next-generation targeted therapeutic combination designed to treat Helicobacter pylori-induced chronic gastritis. | This development addresses growing resistance to standard antibiotic regimes and strengthens the company's gastrointestinal portfolio. |
| 18 June 2025 | Phathom Pharmaceuticals | Phathom Pharmaceuticals secured additional regulatory clearances to expand therapeutic indications for VOQUEZNA in treating erosive mucosal lesions associated with gastric inflammation. | The approval significantly boosts commercial availability and clinical adoption of novel acid-suppressive therapies across specialty care centers. |
| 22 September 2025 | Daewoong Pharmaceutical | Daewoong Pharmaceutical partnered with regional healthcare providers to commercialize its proprietary novel P-CAB agent, Fexuprazan, for acute and chronic gastritis indications across Asia-Pacific markets. | The strategic collaboration expands regional commercial footprint and enhances clinical treatment standard efficiency for gastric mucosal erosion. |
| 14 January 2026 | RedHill Biopharma Ltd. | RedHill Biopharma established a strategic distribution agreement to accelerate the commercial scale-up of Talicia for treating H. pylori infection and associated gastritis. | The agreement enhances market access and long-term treatment compliance for patients with recurrent gastric inflammation. |
Gastritis Treatment Market Scope: Inquiry Before Buying
| Gastritis Treatment Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 5.5 Bn. |
| Forecast Period 2026 to 2034 CAGR: | 4.5% | Market Size in 2034: | USD 8.17 Bn. |
| Segments Covered: | by Drug Class | Acid-blocking medicines Antibiotics Antacids Others |
|
| by Type | Acute Gastritis Chronic Gastritis Erosive Gastritis Non-Erosive Gastritis |
||
| by End User | Government Hospital Medical Practitioners Others |
||
Gastritis Treatment Market, by Region
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, ASEAN, Indonesia, Philippines, Malaysia, Vietnam, Thailand, ASEAN, Rest of Asia Pacific)
Middle East & Africa (South Africa, GCC, Nigeria, Rest of ME&A)
South America (Brazil, Argentina, Rest of South America)
Gastritis Treatment Market: Key Players are
North America
1. Pfizer Inc. – USA
2. AbbVie Inc. – USA
3. Amgen Inc. – USA
4. Bristol-Myers Squibb – USA
5. Johnson & Johnson (Janssen Pharmaceuticals) – USA
6. Takeda Pharmaceuticals USA, Inc. – USA (subsidiary of Japan’s Takeda)
Europe
1. GlaxoSmithKline plc (GSK) – United Kingdom
2. AstraZeneca plc – United Kingdom
3. Bayer AG – Germany
4. Sanofi S.A. – France
5. Novartis AG – Switzerland
6. Boehringer Ingelheim – Germany
Asia-Pacific
1. Takeda Pharmaceutical Company Limited – Japan
2. Dr. Reddy’s Laboratories – India
3. Sun Pharmaceutical Industries Ltd. – India
4. Daiichi Sankyo Company, Limited – Japan
5. Cipla Ltd. – India
6. Aurobindo Pharma Ltd. – India
Frequently Asked Questions:
1) What was the market CAGR of the Global Gastritis Treatment Market during 2026-2034?
Ans - Global Gastritis Treatment Market is expected to grow at a rate of 4.5% CAGR from 2026 to 2034.
2) What is the market segment of the Gastritis Treatment Market?
Ans -The market segments are based on Drug Class, Type and End User.
3) What is the forecast period considered for the Global Gastritis Treatment Market?
Ans -The forecast period for the Global Gastritis Treatment Market is 2026 to 2034.
4) What is the market size of the Global Gastritis Treatment Market in 2034?
Ans – Global Gastritis Treatment Market is estimated as worth USD 8.17 Bn. by 2034.
5) Which region is dominant in the Global Gastritis Treatment Market in 2025?
Ans -In 2025, the North America region dominated the Global Gastritis Treatment Market.